organization · Reporting owner

Fullerton Management Pte Ltd

Disclosed activity across 10 companies

Tapewire entity: 89168
SEC CIK: 0001379348

Reported relationships

Latest disclosed role at each company.

Company	Last reported as	Report date	Published
Coherus Oncology, Inc.CHRS · Entity 6276	10% owner	December 30, 2019	January 08, 2020
Flywire CorpFLYW · Entity 1568	10% owner	May 28, 2021	June 01, 2021
Pear Therapeutics, Inc.PEAR · Entity 114512	10% owner	December 03, 2021	December 10, 2021

Disclosed balances

About these balances

Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.

Coherus Oncology, Inc.

Report date December 30, 2019 · Filed January 08, 2020

Jointly reported with V-Sciences Investments Pte Ltd, Temasek Life Sciences Private Ltd, Temasek Holdings (Private) Ltd

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	7,381,116	Reported balance Holding disclosure · report date 2019-12-30 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 7,381,116 F1: V-Sciences Investments Pte Ltd ("V-Sciences") directly owns 7,381,116 shares of Issuer's common stock. V-Sciences is a wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"), which is a wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which is a wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). Each of Temasek Life Sciences, FMPL and Temasek, through the ownership described herein, may be deemed to beneficially own the shares held by V-Sciences.

Filing footnotes · ownership attribution and instrument terms

F1: V-Sciences Investments Pte Ltd ("V-Sciences") directly owns 7,381,116 shares of Issuer's common stock. V-Sciences is a wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"), which is a wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which is a wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). Each of Temasek Life Sciences, FMPL and Temasek, through the ownership described herein, may be deemed to beneficially own the shares held by V-Sciences.

Flywire Corp

Report date May 28, 2021 · Filed June 01, 2021

Jointly reported with Ossa Investments Pte. Ltd., Hotham Investments Pte. Ltd., Temasek Holdings (Private) Ltd

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A common stockSEC Table I · non-derivative	Direct	0	Last balance in matching sequence After 2021-05-28 transaction · row 3 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 1 · 2021-05-28 · Conversion · Acquired 9,514,293 · Balance 10,635,573 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Row 3 · 2021-05-28 · Other · Disposed 10,635,573 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Class B common stockSEC Table I · non-derivative	Direct	0	Last balance in matching sequence After 2021-05-28 transaction · row 5 Source-order balances reconcile. Account continuity and personal attribution are not independently verified. 2 source rows Row 2 · 2021-05-28 · Conversion · Acquired 1,873,320 · Balance 1,873,320 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments. Row 5 · 2021-05-28 · Other · Disposed 1,873,320 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Voting common stockSEC Table I · non-derivative	Direct	10,635,573	Reported balance After 2021-05-28 transaction · row 4 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 4 · 2021-05-28 · Other · Acquired 10,635,573 · Balance 10,635,573 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Non-voting common stockSEC Table I · non-derivative	Direct	1,873,320	Reported balance After 2021-05-28 transaction · row 6 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 6 · 2021-05-28 · Other · Acquired 1,873,320 · Balance 1,873,320 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Series A preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-05-28 transaction · row 7 Instrument identity requires review; Table II rows are not merged. 1 source row Row 7 · 2021-05-28 · Conversion · Disposed 97,173 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Series B preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-05-28 transaction · row 8 Instrument identity requires review; Table II rows are not merged. 1 source row Row 8 · 2021-05-28 · Conversion · Disposed 2,100,129 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Series C preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-05-28 transaction · row 9 Instrument identity requires review; Table II rows are not merged. 1 source row Row 9 · 2021-05-28 · Conversion · Disposed 547,008 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Series D preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-05-28 transaction · row 10 Instrument identity requires review; Table II rows are not merged. 1 source row Row 10 · 2021-05-28 · Conversion · Disposed 6,625,002 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Series E-2 preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-05-28 transaction · row 11 Instrument identity requires review; Table II rows are not merged. 1 source row Row 11 · 2021-05-28 · Conversion · Disposed 1,873,320 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Series F preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-05-28 transaction · row 12 Instrument identity requires review; Table II rows are not merged. 1 source row Row 12 · 2021-05-28 · Conversion · Disposed 144,981 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7. F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.

Filing footnotes · ownership attribution and instrument terms

F1: Immediately prior to the completion of the Issuer's initial public offering of its voting common stock on May 28, 2021, each share of Series A preferred stock, Series B preferred stock, Series C preferred stock, Series D preferred stock and Series F preferred stock automatically converted into one share of Class A common stock and each share of Series E-2 preferred stock automatically converted into one share of Class B common stock, in each case without payment or further consideration. The preferred stock had no expiration date. Immediately thereafter, but still prior to the completion of the initial public offering, the Class A common stock and Class B common stock were reclassified into voting common stock and non-voting common stock, respectively, in exempt transactions under Rule 16b-7.

F2: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.

Pear Therapeutics, Inc.

Report date December 03, 2021 · Filed December 10, 2021

Jointly reported with Temasek Holdings (Private) Ltd, TLS Beta Pte. Ltd., Temasek Life Sciences Private Ltd, Elbrus Investments Pte. Ltd.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A Common StockSEC Table I · non-derivative	IndirectSee footnotes	26,803,573	Reported balance Holding disclosure · report date 2021-12-03 · row 1 Holding and transaction disclosures are not merged. 1 source row Row 1 · Balance 26,803,573 F1: The securities reported herein consist of 24,903,573 shares of Class A Common Stock of Pear Therapeutics, Inc. (the "Company") directly held by TLS Beta Pte. Ltd and 1,900,000 shares of Class A Common Stock of the Company directly held by Elbrus Investments Pte. Ltd. F2: Each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("TLS"). TLS is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. TLS, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. Each Reporting Owner disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Filing footnotes · ownership attribution and instrument terms

F1: The securities reported herein consist of 24,903,573 shares of Class A Common Stock of Pear Therapeutics, Inc. (the "Company") directly held by TLS Beta Pte. Ltd and 1,900,000 shares of Class A Common Stock of the Company directly held by Elbrus Investments Pte. Ltd.

F2: Each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("TLS"). TLS is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. TLS, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by each of TLS Beta Pte. Ltd. and Elbrus Investments Pte. Ltd. Each Reporting Owner disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Past disclosures · reporting ended (7)

No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.

AMYRIS, INC.

Report date May 07, 2018 · Filed May 09, 2018

Jointly reported with Munday Investments Pte. Ltd., Canhill Investments Pte. Ltd., Temasek Holdings (Private) Ltd

Section 16 reporting ended · disclosed 2018-05-09. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	Direct	3,207,423	Reported balance After 2018-05-07 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-05-07 · Sale · Disposed 95,162 · Balance 3,207,423 F1: On June 5, 2017, the Issuer effected a fifteen-to-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split. F2: Maxwell (Mauritius) Pte Ltd directly owns these shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd.

Filing footnotes · ownership attribution and instrument terms

F1: On June 5, 2017, the Issuer effected a fifteen-to-one reverse stock split of its common stock (the "Reverse Stock Split"). The amount of securities reported on this Form 4 have been adjusted to reflect the Reverse Stock Split.

F2: Maxwell (Mauritius) Pte Ltd directly owns these shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd.

Akili, Inc.

Report date July 02, 2024 · Filed July 05, 2024

Jointly reported with Temasek Holdings (Private) Ltd, TLS Beta Pte. Ltd., Temasek Life Sciences Private Ltd

Section 16 reporting ended · disclosed 2024-07-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common Stock, par value $0.0001SEC Table I · non-derivative	IndirectSee Footnote	0	Reported balance After 2024-07-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2024-07-02 · Other · Disposed 10,336,425 · Balance 0 F1: Reflects disposition of shares of common stock (each, a "Share") of the Issuer at a price per Share of $0.4340 (the "Offer Price") pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2024, by and among the Issuer, Virtual Therapeutics Corporation, a Delaware corporation ("Parent") and Alpha Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer, effective as of July 2, 2024 (the "Effective Time"), with the Issuer surviving the merger. As of the Effective Time, each Share held by the Reporting Persons was converted into the Offer Price. F2: The securities reported herein were directly owned by TLS Beta Pte. Ltd. ("TLS Beta"), which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"). Temasek Life Sciences is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Temasek Life Sciences, FMPL and Temasek Holdings may therefore be deemed to have had or shared beneficial ownership of the securities directly owned by TLS Beta.
Earnout SharesSEC Table II · derivative / convertible security · Expires 2027-08-19	IndirectSee Footnote	0	Reported balance After 2024-07-02 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2024-07-02 · Other · Disposed 1,172,697 · Balance 0 F3: Represents shares of the Issuer's common stock deposited into an escrow account for the benefit of TLS Beta (the "Earnout Shares") pursuant to the Agreement and Plan of Merger, dated as of January 26, 2022, by and among Social Capital Suvretta Holdings Corp. I, Karibu Merger Sub, Inc., and Akili Interactive Labs, Inc. The Earnout Shares were cancelled for no consideration pursuant to the terms of the Merger Agreement. F2: The securities reported herein were directly owned by TLS Beta Pte. Ltd. ("TLS Beta"), which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"). Temasek Life Sciences is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Temasek Life Sciences, FMPL and Temasek Holdings may therefore be deemed to have had or shared beneficial ownership of the securities directly owned by TLS Beta.

Filing footnotes · ownership attribution and instrument terms

F1: Reflects disposition of shares of common stock (each, a "Share") of the Issuer at a price per Share of $0.4340 (the "Offer Price") pursuant to the terms of that certain Agreement and Plan of Merger (the "Merger Agreement"), dated as of May 29, 2024, by and among the Issuer, Virtual Therapeutics Corporation, a Delaware corporation ("Parent") and Alpha Merger Sub, Inc., a Delaware corporation and a wholly-owned subsidiary of Parent ("Purchaser"), Purchaser completed a tender offer for shares of common stock of the Issuer and thereafter merged with and into the Issuer, effective as of July 2, 2024 (the "Effective Time"), with the Issuer surviving the merger. As of the Effective Time, each Share held by the Reporting Persons was converted into the Offer Price.

F2: The securities reported herein were directly owned by TLS Beta Pte. Ltd. ("TLS Beta"), which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited ("Temasek Life Sciences"). Temasek Life Sciences is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Temasek Life Sciences, FMPL and Temasek Holdings may therefore be deemed to have had or shared beneficial ownership of the securities directly owned by TLS Beta.

F3: Represents shares of the Issuer's common stock deposited into an escrow account for the benefit of TLS Beta (the "Earnout Shares") pursuant to the Agreement and Plan of Merger, dated as of January 26, 2022, by and among Social Capital Suvretta Holdings Corp. I, Karibu Merger Sub, Inc., and Akili Interactive Labs, Inc. The Earnout Shares were cancelled for no consideration pursuant to the terms of the Merger Agreement.

Blend Labs, Inc.

Report date July 20, 2021 · Filed July 22, 2021

Jointly reported with Ossa Investments Pte. Ltd., Hotham Investments Pte. Ltd., Temasek Holdings (Private) Ltd

Section 16 reporting ended · disclosed 2021-07-22. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Class A common stockSEC Table I · non-derivative	Direct	11,875,773	Reported balance After 2021-07-20 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2021-07-20 · Conversion · Acquired 11,875,773 · Balance 11,875,773 F1: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F2: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F3: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Series E convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-07-20 transaction · row 2 Instrument identity requires review; Table II rows are not merged. 1 source row Row 2 · 2021-07-20 · Conversion · Disposed 10,949,867 · Balance 0 F2: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F1: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F3: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Series F convertible preferred stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-07-20 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2021-07-20 · Conversion · Disposed 925,906 · Balance 0 F2: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F1: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F3: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Class B common stockSEC Table II · derivative / convertible security	Direct	11,875,773	Reported balance After 2021-07-20 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2021-07-20 · Conversion · Acquired 11,875,773 · Balance 11,875,773 F1: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F2: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F3: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.
Class B common stockSEC Table II · derivative / convertible security	Direct	0	Reported balance After 2021-07-20 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2021-07-20 · Conversion · Disposed 11,875,773 · Balance 0 F1: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred. F2: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date. F3: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.

Filing footnotes · ownership attribution and instrument terms

F1: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock, each share of Class A common stock as then named was reclassified into one share of Class B common stock and each share of Class B common stock as then named was reclassified into one share of Class A common stock. This Form 4 assumes all shares had been renamed as if such reclassification had already occurred.

F2: Immediately prior to the completion of the Issuer's initial public offering of Class A common stock on July 20, 2021, each share of preferred stock automatically converted into one share of Class B common stock and thereafter into one share of Class A common stock without payment or further consideration and has no expiration date.

F3: The securities reported herein are held of record by Ossa Investments Pte. Ltd. ("Ossa Investments"), which is a direct wholly-owned subsidiary of Hotham Investments Pte. Ltd. ("Hotham"). Hotham is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek Holdings"). Hotham, FMPL and Temasek Holdings may therefore be deemed to have or share beneficial ownership of the securities held by Ossa Investments.

Guardant Health, Inc.

Report date October 09, 2018 · Filed October 11, 2018

Jointly reported with TLS Beta Pte. Ltd., Temasek Life Sciences Private Ltd, Temasek Holdings (Private) Ltd

Section 16 reporting ended · disclosed 2018-10-11. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
COMMON STOCKSEC Table I · non-derivative	IndirectBy TLS Beta Pte. Ltd.	1,016,995	Reported balance After 2018-10-09 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-10-09 · Conversion · Acquired 1,016,995 · Balance 1,016,995 F1: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.
COMMON STOCKSEC Table I · non-derivative	IndirectBy TLS Beta Pte. Ltd.	596,012	Reported balance After 2018-10-09 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-10-09 · Conversion · Acquired 596,012 · Balance 596,012 F1: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.
SERIES D PREFERRED STOCKSEC Table II · derivative / convertible security	IndirectBy TLS Beta Pte. Ltd.	0	Reported balance After 2018-10-09 transaction · row 3 Instrument identity requires review; Table II rows are not merged. 1 source row Row 3 · 2018-10-09 · Conversion · Disposed 1,016,995 · Balance 0 F1: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.
SERIES E PREFERRED STOCKSEC Table II · derivative / convertible security	IndirectBy TLS Beta Pte. Ltd.	0	Reported balance After 2018-10-09 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-10-09 · Conversion · Disposed 596,012 · Balance 0 F1: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date. F2: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.

Filing footnotes · ownership attribution and instrument terms

F1: The shares of Preferred Stock automatically converted into shares of the Issuer's Common Stock, for no additional consideration, at the then-effective conversion rate for no additional consideration (subject to the payment of cash in lieu of any fractional shares in accordance with the Certificate of Incorporation) immediately prior to the consummation of the Issuer's initial public offering, and have no expiration date.

F2: The shares are directly held by TLS Beta Pte. Ltd., which is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd, or FMPL, which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited. Temasek Life Sciences Private Limited, FMPL and Temasek Holdings (Private) Limited may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta Pte. Ltd.

PORTOLA PHARMACEUTICALS INC

Report date June 01, 2017 · Filed June 05, 2017

Jointly reported with Munday Investments Pte. Ltd., Canhill Investments Pte. Ltd., Temasek Holdings (Private) Ltd

Section 16 reporting ended · disclosed 2017-06-05. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common stockSEC Table I · non-derivative	Direct	4,133,568	Reported balance After 2017-06-01 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2017-06-01 · Sale · Disposed 1,700,000 · Balance 4,133,568 F1: Maxwell (Mauritius) Pte Ltd ("Maxwell") owns 4,133,568 shares of the Issuer's common stock ("Shares") and V-Sciences Investments Pte Ltd ("V-Sciences") owns 750,000 Shares. Maxwell is wholly owned by Cairnhill Investments (Mauritius) Pte Ltd, which is wholly owned by Fullerton Management Pte Ltd ("FMPL"). V-Sciences is wholly owned by Temasek Life Sciences Private Limited, which is wholly owned by FMPL. FMPL is wholly owned by Temasek Holdings (Private) Limited. Accordingly, each of FMPL and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the 4,883,568 Shares owned by Maxwell and V-Sciences, collectively.

Filing footnotes · ownership attribution and instrument terms

F1: Maxwell (Mauritius) Pte Ltd ("Maxwell") owns 4,133,568 shares of the Issuer's common stock ("Shares") and V-Sciences Investments Pte Ltd ("V-Sciences") owns 750,000 Shares. Maxwell is wholly owned by Cairnhill Investments (Mauritius) Pte Ltd, which is wholly owned by Fullerton Management Pte Ltd ("FMPL"). V-Sciences is wholly owned by Temasek Life Sciences Private Limited, which is wholly owned by FMPL. FMPL is wholly owned by Temasek Holdings (Private) Limited. Accordingly, each of FMPL and Temasek Holdings (Private) Limited, through the ownership described herein, may be deemed to beneficially own the 4,883,568 Shares owned by Maxwell and V-Sciences, collectively.

Q32 Bio Inc.

Report date April 02, 2018 · Filed April 04, 2018

Jointly reported with Temasek Holdings (Private) Ltd, Temasek Life Sciences Private Ltd, TLS Beta Pte. Ltd., V-Sciences Investments Pte Ltd

Section 16 reporting ended · disclosed 2018-04-04. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	1,605,681	Reported balance After 2018-04-02 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2018-04-02 · Conversion · Acquired 1,605,681 · Balance 1,605,681 F1: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F3: Consists of 1,605,681 shares of Common Stock held of record by TLS Beta. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta.
Common StockSEC Table I · non-derivative	IndirectSee footnote	2,595,293	Reported balance After 2018-04-02 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2018-04-02 · Conversion · Acquired 989,612 · Balance 2,595,293 F2: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F4: Consists of 989,612 shares of Common Stock held of record by TLS Beta. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta.
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,220,293	Reported balance After 2018-04-02 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2018-04-02 · Purchase · Acquired 625,000 · Balance 3,220,293 F5: Consists of 625,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $16.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences.
Series A Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnotes	0	Reported balance After 2018-04-02 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2018-04-02 · Conversion · Disposed 1,605,681 · Balance 0 F1: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnotes	0	Reported balance After 2018-04-02 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2018-04-02 · Conversion · Disposed 989,612 · Balance 0 F2: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A Preferred Stock of Homology Medicines, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A Preferred Stock, subject to adjustment and had no expiration date.

F2: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date.

F3: Consists of 1,605,681 shares of Common Stock held of record by TLS Beta.

F4: Consists of 989,612 shares of Common Stock held of record by TLS Beta.

F5: Consists of 625,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $16.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences.

Vir Biotechnology, Inc.

Report date October 16, 2019 · Filed October 18, 2019

Jointly reported with Temasek Holdings (Private) Ltd, Temasek Life Sciences Private Ltd, TLS Beta Pte. Ltd., V-Sciences Investments Pte Ltd

Section 16 reporting ended · disclosed 2019-10-18. Current position is not established by this disclosure.

Security / award	Ownership account	Disclosed shares / units	Disclosure context
Common StockSEC Table I · non-derivative	IndirectSee footnote	3,333,333	Reported balance After 2019-10-16 transaction · row 1 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 1 · 2019-10-16 · Conversion · Acquired 3,333,333 · Balance 3,333,333 F1: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F3: Consists of 3,333,333 shares of Common Stock held of record by TLS Beta. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Common StockSEC Table I · non-derivative	IndirectSee footnote	4,999,999	Reported balance After 2019-10-16 transaction · row 2 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 2 · 2019-10-16 · Conversion · Acquired 1,666,666 · Balance 4,999,999 F2: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F4: Consists of 1,666,666 shares of Common Stock held of record by TLS Beta. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Common StockSEC Table I · non-derivative	IndirectSee footnote	5,499,999	Reported balance After 2019-10-16 transaction · row 3 Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes. 1 source row Row 3 · 2019-10-16 · Purchase · Acquired 500,000 · Balance 5,499,999 F5: Consists of 500,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $20.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Series A-1 Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnotes	0	Reported balance After 2019-10-16 transaction · row 4 Instrument identity requires review; Table II rows are not merged. 1 source row Row 4 · 2019-10-16 · Conversion · Disposed 3,333,333 · Balance 0 F1: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.
Series B Preferred StockSEC Table II · derivative / convertible security	IndirectSee footnotes	0	Reported balance After 2019-10-16 transaction · row 5 Instrument identity requires review; Table II rows are not merged. 1 source row Row 5 · 2019-10-16 · Conversion · Disposed 1,666,666 · Balance 0 F2: The Series B Preferred Stock of the Issuer held of record by TLS Beta automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series B Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series B Preferred Stock, subject to adjustment and had no expiration date. F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Filing footnotes · ownership attribution and instrument terms

F1: The Series A-1 Preferred Stock of Vir Biotechnology, Inc. (the "Issuer") held of record by TLS Beta Pte. Ltd. ("TLS Beta") automatically converted into Common Stock on a 1:1 basis immediately prior to the closing of the initial public offering of the Issuer. Pursuant to the Amended and Restated Certificate of Incorporation of the Issuer, the shares of Series A-1 Preferred Stock had been convertible, at the option of the holder, at any time into shares of Common Stock at an initial conversion rate equal to one share of Common Stock per share of Series A-1 Preferred Stock, subject to adjustment and had no expiration date.

F3: Consists of 3,333,333 shares of Common Stock held of record by TLS Beta.

F4: Consists of 1,666,666 shares of Common Stock held of record by TLS Beta.

F5: Consists of 500,000 shares of Common Stock held of record by V-Sciences Investments Pte Ltd ("V-Sciences") which were purchased in the Issuer's initial public offering at a price of $20.00 per share. V-Sciences Investments Pte Ltd is a direct wholly-owned subsidiary of Temasek Life Sciences Private Limited. Temasek Life Sciences Private Limited ("TLS") is a direct wholly-owned subsidiary of Fullerton Management Pte Ltd ("FMPL"), which in turn is a direct wholly-owned subsidiary of Temasek Holdings (Private) Limited ("Temasek"). TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by V-Sciences. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

F6: TLS Beta is a direct wholly-owned subsidiary of TLS. TLS is a direct wholly-owned subsidiary of FMPL, which in turn is a direct wholly-owned subsidiary of Temasek. TLS, FMPL and Temasek may therefore be deemed to have or share beneficial ownership of the securities held by TLS Beta. Each Reporting Person disclaims beneficial ownership of such shares except to the extent of its pecuniary interest therein, and the inclusion of these securities in this report shall not be deemed an admission of beneficial ownership of the reported securities for purposes of Section 16 or for any other purposes.

Transaction history

JSON API

Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”

The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.

Transaction date	Company	Activity / security	Shares / units	Reported price	Reported value	Details
November 09, 2016 Filed Nov 14, 2016 11:36 UTC	AMYRIS, INC. AMRS · Entity 91367	SaleCommon Stock	412,711	$0.81	$333,594.30	Disclosure SEC source: 0000899243-16-033245 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,934,461 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 63,919,268 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document
November 08, 2016 Filed Nov 9, 2016 11:32 UTC	AMYRIS, INC. AMRS · Entity 91367	SaleCommon Stock	311,136	$0.82	$254,042.54	Disclosure SEC source: 0000899243-16-032978 · doc4.xml · nonDerivative · entry 2 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,347,172 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 64,347,172 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document
November 07, 2016 Filed Nov 9, 2016 11:32 UTC	AMYRIS, INC. AMRS · Entity 91367	SaleCommon Stock	22,675	$0.80	$18,146.80	Disclosure SEC source: 0000899243-16-032978 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,658,308 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 64,347,172 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document
November 04, 2016 Filed Nov 7, 2016 11:20 UTC	AMYRIS, INC. AMRS · Entity 91367	SaleCommon Stock	221,320	$0.81	$178,472.45	Disclosure SEC source: 0000899243-16-032788 · doc4.xml · nonDerivative · entry 2 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,680,983 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 64,680,983 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document
November 03, 2016 Filed Nov 7, 2016 11:20 UTC	AMYRIS, INC. AMRS · Entity 91367	SaleCommon Stock	2,389,913	$0.90	$2,146,380.87	Disclosure SEC source: 0000899243-16-032788 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 64,902,303 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 64,680,983 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document
October 17, 2016 Filed Oct 18, 2016 11:27 UTC	AMYRIS, INC. AMRS · Entity 91367	SaleCommon Stock	1,680,345	$0.85	$1,425,604.70	Disclosure SEC source: 0000899243-16-031799 · doc4.xml · nonDerivative · entry 2 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 67,292,216 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 67,292,216 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document
October 14, 2016 Filed Oct 18, 2016 11:27 UTC	AMYRIS, INC. AMRS · Entity 91367	SaleCommon Stock	619,655	$0.79	$486,553.11	Disclosure SEC source: 0000899243-16-031799 · doc4.xml · nonDerivative · entry 1 Maxwell (Mauritius) Pte Ltd · CIK 0001512375 · 10% owner Cairnhill Investments (Mauritius) Pte Ltd · CIK 0001434871 · 10% owner Fullerton Management Pte Ltd · CIK 0001379348 · 10% owner Temasek Holdings (Private) Ltd · CIK 0001021944 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 68,972,561 F1 · ownership.direct: Maxwell (Mauritius) Pte Ltd directly owns 67,292,216 shares of Common Stock. Maxwell (Mauritius) Pte Ltd is wholly-owned by Cairnhill Investments (Mauritius) Pte Ltd, which in turn is wholly-owned by Fullerton Management Pte Ltd, which in turn is wholly-owned by Temasek Holdings (Private) Limited. Therefore, each of Temasek Holdings (Private) Limited, Fullerton Management Pte Ltd and Cairnhill Investments (Mauritius) Pte Ltd may be deemed to beneficially own the shares of Common Stock directly owned by Maxwell (Mauritius) Pte Ltd. Read SEC document

Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.